On May 17, 2026, International Neurofibromatosis Awareness Day, AstraZeneca Morocco and the Moroccan Association of Neurofibromatosis (AMNF) held an event to advocate for the recognition of neurofibromatosis as a long-term illness (ALD) in Morocco. The initiative aimed to improve patient access to care and reduce the financial burden on families.
Neurofibromatosis is a genetic disorder that causes tumors to grow on nerves and can lead to various complications, including hearing loss, learning disabilities, and cardiovascular issues. According to the AMNF, the condition affects approximately 1 in 3,000 people worldwide, but in Morocco, many cases remain undiagnosed due to lack of awareness.
The event featured medical experts who emphasized the need for a national registry and specialized treatment centers. Dr. Fatima Zahra, a neurologist at the University Hospital of Casablanca, stated, 'Early diagnosis and multidisciplinary care are crucial for improving outcomes, but without ALD status, many patients cannot afford regular follow-ups.'
AstraZeneca Morocco reaffirmed its commitment to supporting patient advocacy groups and funding research. The company's representative noted, 'We are proud to collaborate with AMNF to bring attention to this often-overlooked disease and to push for policy changes that can transform lives.'
The AMNF plans to submit a formal proposal to the Ministry of Health by June 2026, requesting that neurofibromatosis be added to the list of ALDs covered by the national health insurance system.
